Stay updated with breaking news from John Drayton Wise. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Insmed Incorporated (NASDAQ:INSM – Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 9,930,000 shares, a growth of 16.4% from the April 30th total of 8,530,000 shares. Based on an average daily volume of 1,760,000 shares, the […]
Eagle Asset Management Inc. lifted its stake in Insmed Incorporated (NASDAQ:INSM – Free Report) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 548,633 shares of the biopharmaceutical company’s stock after purchasing an additional 29,555 shares during the […]
Insmed Incorporated (NASDAQ:INSM – Get Free Report) saw unusually-high trading volume on Thursday after TD Cowen raised their price target on the stock from $45.00 to $67.00. TD Cowen currently has a buy rating on the stock. Approximately 2,243,974 shares changed hands during trading, an increase of 3% from the previous session’s volume of 2,186,428 […]
Insmed (NASDAQ:INSM – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $52.00 to $70.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 22.85% from the […]
Bank of America reaffirmed their buy rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Bank of America currently has a $40.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on INSM. Barclays raised their […]